NO20200670A1 - Sammensetninger og fremgangsmåter for modulering av hemostase - Google Patents

Sammensetninger og fremgangsmåter for modulering av hemostase

Info

Publication number
NO20200670A1
NO20200670A1 NO20200670A NO20200670A NO20200670A1 NO 20200670 A1 NO20200670 A1 NO 20200670A1 NO 20200670 A NO20200670 A NO 20200670A NO 20200670 A NO20200670 A NO 20200670A NO 20200670 A1 NO20200670 A1 NO 20200670A1
Authority
NO
Norway
Prior art keywords
compositions
methods
modulating hemostasis
hemostasis
modulating
Prior art date
Application number
NO20200670A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20200670A1 publication Critical patent/NO20200670A1/no
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20200670A 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase NO20200670A1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15
PCT/US2006/060927 WO2007059513A2 (en) 2005-11-15 2006-11-15 Compositions and methods for modulating hemostasis

Publications (1)

Publication Number Publication Date
NO20200670A1 true NO20200670A1 (no) 2008-07-30

Family

ID=38049397

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20082182A NO345177B1 (no) 2005-11-15 2008-05-13 Sammensetninger og fremgangsmåter for modulering av hemostase
NO20200671A NO20200671A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase
NO20200670A NO20200670A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20082182A NO345177B1 (no) 2005-11-15 2008-05-13 Sammensetninger og fremgangsmåter for modulering av hemostase
NO20200671A NO20200671A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase

Country Status (25)

Country Link
US (4) US8383386B2 (no)
EP (4) EP2431389A1 (no)
JP (4) JP5823088B2 (no)
KR (4) KR101600158B1 (no)
CN (1) CN101356192B (no)
AU (1) AU2006315175B2 (no)
BR (1) BRPI0618654B1 (no)
CA (2) CA2971971A1 (no)
CR (1) CR9956A (no)
DK (1) DK1948690T3 (no)
EC (1) ECSP088452A (no)
ES (2) ES2496567T3 (no)
GT (1) GT200800065A (no)
IL (1) IL191310A (no)
MX (3) MX336958B (no)
MY (1) MY162181A (no)
NO (3) NO345177B1 (no)
NZ (1) NZ568108A (no)
PL (1) PL1948690T3 (no)
PT (1) PT1948690E (no)
RU (2) RU2008123398A (no)
SI (1) SI1948690T1 (no)
SV (1) SV2008002906A (no)
WO (1) WO2007059513A2 (no)
ZA (1) ZA200804026B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
PT2453910T (pt) 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
CA2812888A1 (en) 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
EP2950813B1 (en) * 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
MY173548A (en) * 2013-09-24 2020-02-04 Pfizer Fxa variant compositions
JP6629744B2 (ja) * 2013-11-01 2020-01-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 第Ｘａ因子の半減期を延ばす組成物および方法
PT3096779T (pt) * 2014-01-24 2020-02-21 Pfizer Composições e métodos para tratamento de hemorragia intracerebral
PL3149163T3 (pl) * 2014-05-26 2020-12-28 Academisch Ziekenhuis Leiden Białka prohemostatyczne do leczenia krwawienia
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
KR20110114587A (ko) * 2008-12-19 2011-10-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도

Also Published As

Publication number Publication date
WO2007059513A2 (en) 2007-05-24
JP2016005464A (ja) 2016-01-14
RU2011130932A (ru) 2013-01-27
US20140120155A1 (en) 2014-05-01
PT1948690E (pt) 2014-09-08
KR101600158B1 (ko) 2016-03-08
DK1948690T3 (da) 2014-09-01
NO345177B1 (no) 2020-10-26
EP2431389A1 (en) 2012-03-21
AU2006315175B2 (en) 2013-02-07
CR9956A (es) 2008-08-21
BRPI0618654A2 (pt) 2011-09-06
SV2008002906A (es) 2008-10-22
BRPI0618654B1 (pt) 2021-10-19
MX337059B (es) 2016-02-09
BRPI0618654A8 (pt) 2019-01-15
RU2008123398A (ru) 2009-12-27
US20160362673A1 (en) 2016-12-15
RU2570547C2 (ru) 2015-12-10
CN101356192A (zh) 2009-01-28
CA2629491A1 (en) 2007-05-24
CN101356192B (zh) 2013-09-11
US9896676B2 (en) 2018-02-20
KR101827569B1 (ko) 2018-02-09
EP2423224B1 (en) 2015-08-12
WO2007059513A3 (en) 2007-11-29
EP1948690A2 (en) 2008-07-30
MX2008006313A (es) 2008-11-06
JP6236194B2 (ja) 2017-11-22
EP2423224A1 (en) 2012-02-29
NO20082182L (no) 2008-07-30
EP2431390B1 (en) 2015-08-12
US20180251745A1 (en) 2018-09-06
US9410137B2 (en) 2016-08-09
MX336958B (es) 2016-02-05
PL1948690T3 (pl) 2014-11-28
EP2431390A1 (en) 2012-03-21
EP1948690A4 (en) 2009-06-17
NO20200671A1 (no) 2008-07-30
JP2009515559A (ja) 2009-04-16
KR20140005383A (ko) 2014-01-14
US8383386B2 (en) 2013-02-26
NZ568108A (en) 2011-09-30
MY162181A (en) 2017-05-31
US20090175931A1 (en) 2009-07-09
HK1165444A1 (en) 2012-10-05
IL191310A (en) 2015-06-30
CA2629491C (en) 2019-05-07
HK1128699A1 (en) 2009-11-06
KR20080078664A (ko) 2008-08-27
ES2496567T3 (es) 2014-09-19
JP5957167B2 (ja) 2016-07-27
JP2018033459A (ja) 2018-03-08
JP6571735B2 (ja) 2019-09-04
KR20160029135A (ko) 2016-03-14
ES2549929T3 (es) 2015-11-03
KR20140115374A (ko) 2014-09-30
JP5823088B2 (ja) 2015-11-25
KR101574042B1 (ko) 2015-12-03
AU2006315175A1 (en) 2007-05-24
GT200800065A (es) 2008-11-03
ZA200804026B (en) 2009-10-28
SI1948690T1 (sl) 2014-09-30
EP1948690B1 (en) 2014-06-11
ECSP088452A (es) 2008-07-30
CA2971971A1 (en) 2007-05-24
JP2014073127A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
NO20200671A1 (no) Sammensetninger og fremgangsmåter for modulering av hemostase
LTC2548560I2 (lt) Kompozicijos ir būdai, skirti SMN2 splaisingo moduliavimui
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
IL185708A0 (en) Methods and compositions for modulating hyperstabilized c-met
DK1969391T3 (da) Tyndfilm emitter-absorber indretning og fremgangsmåde
EP1940423A4 (en) METHODS AND COMPOSITIONS OF TISSUE GENIUS
IL194788A0 (en) Compositions and methods for modulating vascular development
DK1858488T4 (da) Tigecyclinsammensætninger og fremgangsmåder til fremstilling deraf
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK2063907T3 (da) Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
DE602006006476D1 (de) Verschluss
DK2089047T3 (da) Sammensætninger og fremgangsmåder til beskyttelse og regenerering af hjerte-væv
DK1891208T3 (da) Hidtil ukendte cellulære sammensætninger og fremgangsmåder til fremstilling deraf
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
EP1896050A4 (en) LKKTET AND / OR LKKTNT PEPTIDE COMPOSITIONS AND METHODS
EP1951050A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
DE602006021027D1 (de) Verschluss
DE602006020623D1 (de) Fälschungssicherer verschluss
IL185753A0 (en) Methods and compositions for modulating vascular integrity
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
DK1957050T3 (da) Polypeptidfilm og fremgangsmåder
EP1957486A4 (en) COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
EP1763358A4 (en) COMPOSITIONS AND METHODS FOR SUPPRESSING THE APPETITE
PL1858481T3 (pl) Kompozycje oftalmologiczne i ich zastosowanie
DK1846531T3 (da) Spotting-fluidumsammensætninger og dertil hørende fremgangsmåder